The FDA has released briefing documents detailing its concerns for AstraZeneca’s cancer drugs camizestrant and Truqap ahead ...
AstraZeneca is expanding its prospects in cardiometabolic disease, paying $1.2 billion to begin a partnership on eight programs that include obesity drug candidates with potential advantages over ...
AstraZeneca has ended work on one of its potential drugs for fatty liver disease after viewing disappointing data from a phase 2 study. The U.K.-based pharma had been evaluating the antisense ...
The coronavirus vaccine developed by AstraZeneca (NASDAQ: AZN) in partnership with Oxford University has succeeded in preventing transmission of COVID-19. Unfortunately, a disappointing series of ...
Zacks Investment Research on MSN
AstraZeneca's Ultomiris meets goal in rare kidney disease study
AstraZeneca AZN announced positive results from an interim analysis of the ongoing late-stage I CAN study, which evaluated its blockbuster rare disease drug Ultomiris (ravulizumab) for IgA nephropathy ...
April 2 (Reuters) - AstraZeneca (AZN.L), opens new tab said on Thursday that a combination treatment with its cancer drug Imfinzi showed significant improvement in how long patients with a common ...
AstraZeneca will pay CSPC upfront fee of $110 million Additional potential payments of up to $5.22 billion to CSPC Deal latest of AstraZeneca efforts to bolster China business, AI The deal marks the ...
(Reuters) -AstraZeneca has proposed price cuts to its drugs in the United States, its CEO said on Tuesday, days after unveiling a $50 billion investment to expand there, as President Donald Trump ...
The U.S. Food and Drug Administration (FDA) said the safety risks associated with Andexxa now outweigh its benefits, prompting AstraZeneca Plc (NASDAQ: AZN) to seek a voluntary withdrawal of the ...
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announces the launch of AstraZeneca Direct, an online platform designed to create a simple, convenient way for eligible patients to access their ...
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN), the FTSE 100 pharmaceuticals giant, faces no material risk from its Japanese partner ...
LONDON (Reuters) – The COVAX vaccine-sharing plan said on Thursday it is seeking to bolster its supplies of COVID-19 vaccines for poor countries from new manufacturers as it aims to mitigate supply ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results